Grail
Healthcare & Life Sci
Company overview
GRAIL is a biotech company focused on cancer detection through blood-based testing. Its mission is to detect cancer early, when it can be cured. Its main product is the Galleri test, a multi-cancer early detection blood test that can screen for over 50 cancer types before they cause symptoms.
GRAIL was founded in 2015 in San Francisco, originally as a subsidiary of Illumina before being acquired outright in 2021. It's now a public company, trading on Nasdaq under the ticker GRAL, with Illumina keeping a 14.5% stake after the 2024 spinoff. In 2024, it had revenue of $126 million and about 1,000 employees, headquartered in Menlo Park, California. Grail is a top-tier H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Menlo Park, United States